MB
MDGL icon

MPM BioImpact’s Madrigal Pharmaceuticals MDGL Stock Holding History

MPM BioImpact’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-96,780
Closed -$56.4M – 42
2025
Q4 		$56.4M Sell
96,780
-3,635
-4% -$1.86M 6.45% 2
2025
Q3 		$46.1M Hold
100,415
– – 7.54% 1
2025
Q2 		$30.4M Hold
100,415
– – 5.27% 2
2025
Q1 		$33.3M Buy
+100,415
New +$33M 5.72% 2
2024
Q4 		– Sell
-72,395
Closed -$15.4M – 50
2024
Q3 		$15.4M Buy
72,395
+1,210
+2% +$310K 2.3% 15
2024
Q2 		$19.9M Buy
71,185
+9,786
+16% +$2.33M 3.1% 6
2024
Q1 		$16.4M Buy
61,399
+20,489
+50% +$4.83M 2.64% 9
2023
Q4 		$9.47M Buy
40,910
+51
+0.1% +$8.92K 2.21% 16
2023
Q3 		$5.97M Buy
40,859
+2,848
+7% +$536K 1.59% 22
2023
Q2 		$8.78M Buy
38,011
+1,973
+5% +$534K 1.77% 17
2023
Q1 		$8.73M Buy
36,038
+9,265
+35% +$2.52M 2.27% 14
2022
Q4 		$7.77M Sell
26,773
-17,974
-40% -$1.76M 2.02% 14
2022
Q3 		$2.91M Sell
44,747
-253
-0.6% -$17.6K 0.69% 27
2022
Q2 		$3.22M Buy
+45,000
New +$3.31M 0.89% 25

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MPM BioImpact's MDGL Position: Q1 2026 in Review

MPM BioImpact sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 96,780 shares — an estimated $56.4M sold.

MPM BioImpact first reported a position in MDGL in Q2 2022 and held it in 14 quarters. The position peaked at $56.4M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • MPM BioImpact reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • MPM BioImpact sold 96,780 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $56.4M.
  • MPM BioImpact first reported a position in Madrigal Pharmaceuticals in Q2 2022 and held it in 14 quarters.
  • MPM BioImpact's Madrigal Pharmaceuticals position peaked at $56.4M in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on MPM BioImpact's 13F filing for Q1 2026, filed 15 May 2026.